TY  - JOUR
T1  - Pharmacovigilance Investigation of Tyrosine Kinase Inhibitors: Evaluation of Adverse Events
A1  - Saki Kobayashi
A1  - Yuuki Tanaka
A1  - Emi Suzuki
JF  - Annals of Pharmacy Practice and Pharmacotherapy
JO  - Ann Pharm Pract Pharmacother
SN  - 3062-4436
Y1  - 2025
VL  - 5
IS  - 1
DO  - 10.51847/adhCcj8ofU
SP  - 67
EP  - 73
N2  - This study aimed to examine adverse drug reaction (ADR) reports documented in the scientific literature that occurred during or after the administration of kinase inhibitors in patients treated for rheumatologic disorders, focusing on identifying their nature, prevalence, and severity. A systematic search was carried out in the MEDLINE and PubMed databases covering the period from January 2005 to May 2022. Out of 291 retrieved publications, only those meeting the inclusion criteria were selected for data extraction. Descriptive and variation analyses served as the primary statistical approaches, including the calculation of mean values, standard deviations, ranges, and 95% confidence intervals. The PICOS framework was applied to assess study outcomes. The investigated cohort comprised individuals diagnosed with rheumatologic as well as oncologic conditions. Growing attention has been directed toward the safety monitoring of kinase inhibitors, given their status as an emerging and dependable pharmacological category. Understanding the safety characteristics of these agents continues to hold clinical significance. A thorough evaluation of the full-text sources suggests that the notable number of reported serious ADRs likely reflects heightened awareness and publication activity rather than an actual increase in their occurrence.
UR  - https://galaxypub.co/article/pharmacovigilance-investigation-of-tyrosine-kinase-inhibitors-evaluation-of-adverse-events-47ecgt0yuzoir2s
ER  -